ABC.L Regulatory News (ABC)

29 December 2011

ABCAM PLC ("Abcam" or "the Company")

Additional Listing

Application has been made to AIM for the block listing of 1,350,000 ordinary shares of 0.2p each in the Company. These shares will be issued as appropriate, over time, in connection with the following option schemes:

150,000 under the Abcam plc Share Incentive Plan

500,000 under the Abcam 2009 Company Share Option Plan

700,000 under the Abcam plc Long Term Incentive Plan

When issued, the shares will rank pari passu in all respects with the existing shares in issue. It is expected that the block listing will become effective on 3 January 2012.

For further information please contact:

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 325 staff across its six operating companies.

Abcam now has an online catalogue of over 82,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.